Fatih Aydoğan1, Akif Enes Arıkan2, Erman Aytaç2, Mehmet Velidedeoğlu2, Mehmet Halit Yılmaz3, Muhammet Sait Sager4, Varol Çelik1, Cihan Uras1. 1. Department of General Surgery, Breast Diseases Service, İstanbul University, Cerrahpaşa Medical Faculty İstanbul, Turkey. 2. Department of General Surgery, İstanbul University, Cerrahpaşa Medical Faculty İstanbul, Turkey. 3. Department of Radiology, İstanbul University, Cerrahpaşa Medical Faculty İstanbul, Turkey. 4. Department of Nuclear Medicine, İstanbul University, Cerrahpaşa Medical Faculty İstanbul, Turkey.
Abstract
OBJECTIVE: Sentinel lymph node biopsy can be applied by using either blue dye or radionuclide method or both in breast cancer. Fluorescent imaging with indocyanine green is a new defined method. This study evaluates the applicability of sentinel lymph node biopsy via fluorescent indocyanine green. MATERIAL AND METHODS: IC-VIEW (Pulsion Medical Systems AG, Munich, Germany) infrared visualization system was used for imaging. Two mL of indocyanine green was injected to visualize sentinel lymph nodes. After injection, subcutaneous lymphatics were traced and sentinel lymph nodes were found with simultaneous imaging. Sentinel lymph nodes were excised under fluorescent light guidance, and excised lymph nodes were examined histopathologically. Patients with sentinel lymph node metastases underwent axillary dissection. RESULTS: Four patients with sentinel lymph node biopsy due to breast cancer were included in the study. Sentinel lymph nodes were visualized with indocyanine green in all patients. The median number of excised sentinel lymph node was 2 (2-3). Two patients with lymph node metastasis underwent axillary dissection. No metastasis was detected in lymph nodes other than the sentinel nodes in patients with axillary dissection. There was no complication during and after the operation related to the method. CONCLUSION: According to our limited experience, sentinel lymph node biopsy under fluorescent indocyanine green guidance, which has an advantage of simultaneous visualization, is technically feasible.
OBJECTIVE: Sentinel lymph node biopsy can be applied by using either blue dye or radionuclide method or both in breast cancer. Fluorescent imaging with indocyanine green is a new defined method. This study evaluates the applicability of sentinel lymph node biopsy via fluorescent indocyanine green. MATERIAL AND METHODS: IC-VIEW (Pulsion Medical Systems AG, Munich, Germany) infrared visualization system was used for imaging. Two mL of indocyanine green was injected to visualize sentinel lymph nodes. After injection, subcutaneous lymphatics were traced and sentinel lymph nodes were found with simultaneous imaging. Sentinel lymph nodes were excised under fluorescent light guidance, and excised lymph nodes were examined histopathologically. Patients with sentinel lymph node metastases underwent axillary dissection. RESULTS: Four patients with sentinel lymph node biopsy due to breast cancer were included in the study. Sentinel lymph nodes were visualized with indocyanine green in all patients. The median number of excised sentinel lymph node was 2 (2-3). Two patients with lymph node metastasis underwent axillary dissection. No metastasis was detected in lymph nodes other than the sentinel nodes in patients with axillary dissection. There was no complication during and after the operation related to the method. CONCLUSION: According to our limited experience, sentinel lymph node biopsy under fluorescent indocyanine green guidance, which has an advantage of simultaneous visualization, is technically feasible.
Authors: Christine E Dauphine; Iraj Khalkhali; M Perla Vargas; Nova M Isaac; Jason Haukoos; Hernan I Vargas Journal: Am J Surg Date: 2006-10 Impact factor: 2.565
Authors: Anne Fleissig; Lesley J Fallowfield; Carolyn I Langridge; Leigh Johnson; Robert G Newcombe; J Michael Dixon; Mark Kissin; Robert E Mansel Journal: Breast Cancer Res Treat Date: 2005-09-15 Impact factor: 4.872
Authors: R G Pleijhuis; G C Langhout; W Helfrich; G Themelis; A Sarantopoulos; L M A Crane; N J Harlaar; J S de Jong; V Ntziachristos; G M van Dam Journal: Eur J Surg Oncol Date: 2010-11-24 Impact factor: 4.424